Does the media refer more to AUTL or IMDX?

In the previous week, Oncocyte had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Oncocyte and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Oncocyte's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMDX or ENTX more profitable?

Entera Bio has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Oncocyte -2,955.63% N/A -107.52% Entera Bio N/A -147.19% -103.22%

Does the media favor IMDX or ENTX?

In the previous week, Oncocyte had 2 more articles in the media than Entera Bio. MarketBeat recorded 6 mentions for Oncocyte and 4 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.12 beat Oncocyte's score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, KMDA or IMDX?

Kamada has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.65 $20.20M $0.38 21.87 Oncocyte $4.05M 27.79 -$50.22M -$1.49 N/A

Is KMDA or IMDX more profitable?

Kamada has a net margin of 11.60% compared to Oncocyte's net margin of -2,955.63%. Kamada's return on equity of 8.37% beat Oncocyte's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Oncocyte -2,955.63% N/A -107.52%

Does the media refer more to KMDA or IMDX?

In the previous week, Kamada had 12 more articles in the media than Oncocyte. MarketBeat recorded 18 mentions for Kamada and 6 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.00 beat Kamada's score of -0.43 indicating that Oncocyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PBYI or IMDX?

In the previous week, Oncocyte had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Oncocyte and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncocyte (IMDX) Competitors

$3.44 -0.03 (-0.86%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.52 +0.08 (+2.18%)

As of 10/2/2026 07:30 PM Eastern

Compare

IMDX vs. AUTL, ENTX, KMDA, MPLT, and PBYI

Should you buy Oncocyte stock or one of its competitors? Oncocyte's main competitors and comparable companies include Autolus Therapeutics (AUTL), Entera Bio (ENTX), Kamada (KMDA), Maplight Therapeutics (MPLT), and Puma Biotechnology (PBYI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncocyte compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Autolus Therapeutics has a net margin of -238.66% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Oncocyte	-2,955.63%	N/A	-107.52%

In the previous week, Oncocyte had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Oncocyte and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Oncocyte's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autolus Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 461.80%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 205.23%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Oncocyte has lower revenue, but higher earnings than Autolus Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A
Oncocyte	$4.05M	27.79	-$50.22M	-$1.49	N/A

Summary

Autolus Therapeutics beats Oncocyte on 13 of the 17 factors compared between the two stocks.

How does Oncocyte compare to Entera Bio?

Oncocyte (NASDAQ:IMDX) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entera Bio has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Entera Bio	N/A	-147.19%	-103.22%

Entera Bio has lower revenue, but higher earnings than Oncocyte. Entera Bio is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	27.79	-$50.22M	-$1.49	N/A
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A

Oncocyte has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, Oncocyte had 2 more articles in the media than Entera Bio. MarketBeat recorded 6 mentions for Oncocyte and 4 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.12 beat Oncocyte's score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 205.23%. Entera Bio has a consensus price target of $9.60, suggesting a potential upside of 235.66%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts plainly believe Entera Bio is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Entera Bio beats Oncocyte on 10 of the 16 factors compared between the two stocks.

How does Oncocyte compare to Kamada?

Kamada (NASDAQ:KMDA) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Kamada has a net margin of 11.60% compared to Oncocyte's net margin of -2,955.63%. Kamada's return on equity of 8.37% beat Oncocyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Oncocyte	-2,955.63%	N/A	-107.52%

Kamada has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kamada has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.65	$20.20M	$0.38	21.87
Oncocyte	$4.05M	27.79	-$50.22M	-$1.49	N/A

Kamada presently has a consensus target price of $13.50, indicating a potential upside of 62.45%. Oncocyte has a consensus target price of $10.50, indicating a potential upside of 205.23%. Given Oncocyte's higher probable upside, analysts plainly believe Oncocyte is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Kamada had 12 more articles in the media than Oncocyte. MarketBeat recorded 18 mentions for Kamada and 6 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.00 beat Kamada's score of -0.43 indicating that Oncocyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats Oncocyte on 11 of the 16 factors compared between the two stocks.

How does Oncocyte compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Oncocyte has higher revenue and earnings than Maplight Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Oncocyte	$4.05M	27.79	-$50.22M	-$1.49	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Oncocyte	-2,955.63%	N/A	-107.52%

Maplight Therapeutics currently has a consensus price target of $29.50, indicating a potential upside of 200.41%. Oncocyte has a consensus price target of $10.50, indicating a potential upside of 205.23%. Given Oncocyte's higher possible upside, analysts clearly believe Oncocyte is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Oncocyte had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Oncocyte and 0 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Overall Sentiment
Maplight Therapeutics	Neutral
Oncocyte	Neutral

55.4% of Oncocyte shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Maplight Therapeutics and Oncocyte tied by winning 7 of the 14 factors compared between the two stocks.

How does Oncocyte compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

In the previous week, Oncocyte had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Oncocyte and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.15	$31.11M	$0.52	18.29
Oncocyte	$4.05M	27.79	-$50.22M	-$1.49	N/A

Puma Biotechnology has a net margin of 11.50% compared to Oncocyte's net margin of -2,955.63%. Puma Biotechnology's return on equity of 20.76% beat Oncocyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Oncocyte	-2,955.63%	N/A	-107.52%

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 36.91%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 205.23%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts plainly believe Oncocyte is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Puma Biotechnology has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 2.2% of Oncocyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Puma Biotechnology beats Oncocyte on 9 of the 15 factors compared between the two stocks.

Get Oncocyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMDX vs. The Competition

Export

Metric	Oncocyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.55M	$3.87B	$7.13B	$13.14B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-2.31	12.93	273.77	26.04
Price / Sales	27.79	1,287.36	614.30	85.58
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	-3.13	16.63	10.92	6.30
Net Income	-$50.22M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-12.24%	-3.10%	-2.07%	-1.67%
1 Month Performance	-16.50%	-10.70%	-6.21%	-4.51%
1 Year Performance	N/A	19.46%	7.45%	2.03%

Oncocyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMDX Oncocyte	1.4562 of 5 stars	$3.44 -0.9%	$10.50 +205.2%	N/A	$113.55M	$4.05M	N/A	58	News Coverage Analyst Downgrade
AUTL Autolus Therapeutics	3.3651 of 5 stars	$1.94 flat	$10.00 +415.5%	+10.6%	$516.35M	$75.39M	N/A	752
ENTX Entera Bio	3.5772 of 5 stars	$2.96 flat	$9.00 +204.1%	+52.1%	$514.55M	$40K	N/A	21
KMDA Kamada	4.8614 of 5 stars	$8.74 -1.2%	$13.50 +54.5%	+22.2%	$508.92M	$191.85M	23.00	462	Analyst Revision
MPLT Maplight Therapeutics	3.0671 of 5 stars	$10.90 -0.2%	$29.50 +170.6%	N/A	$506.45M	N/A	N/A	133	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMDX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncocyte (IMDX) Competitors

IMDX vs. AUTL, ENTX, KMDA, MPLT, and PBYI

How does Oncocyte compare to Autolus Therapeutics?

Summary

How does Oncocyte compare to Entera Bio?

Summary

How does Oncocyte compare to Kamada?

Summary

How does Oncocyte compare to Maplight Therapeutics?

Summary

How does Oncocyte compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncocyte (IMDX) Competitors

IMDX vs. AUTL, ENTX, KMDA, MPLT, and PBYI

How does Oncocyte compare to Autolus Therapeutics?

Which has more volatility & risk, AUTL or IMDX?

Do insiders and institutionals hold more shares of AUTL or IMDX?

Is AUTL or IMDX more profitable?

Does the media refer more to AUTL or IMDX?

Do analysts recommend AUTL or IMDX?

Which has preferable earnings and valuation, AUTL or IMDX?

Summary

How does Oncocyte compare to Entera Bio?

Do insiders and institutionals hold more shares of IMDX or ENTX?

Is IMDX or ENTX more profitable?

Which has better valuation and earnings, IMDX or ENTX?

Which has more volatility & risk, IMDX or ENTX?

Does the media favor IMDX or ENTX?

Do analysts recommend IMDX or ENTX?

Summary

How does Oncocyte compare to Kamada?

Is KMDA or IMDX more profitable?

Which has more volatility and risk, KMDA or IMDX?

Do institutionals and insiders believe in KMDA or IMDX?

Which has preferable valuation and earnings, KMDA or IMDX?

Do analysts prefer KMDA or IMDX?

Does the media refer more to KMDA or IMDX?

Summary

How does Oncocyte compare to Maplight Therapeutics?

Which has stronger earnings & valuation, MPLT or IMDX?

Is MPLT or IMDX more profitable?

Do analysts rate MPLT or IMDX?

Does the media favor MPLT or IMDX?

Do institutionals and insiders believe in MPLT or IMDX?

Summary

How does Oncocyte compare to Puma Biotechnology?

Does the media favor PBYI or IMDX?

Which has preferable valuation and earnings, PBYI or IMDX?

Is PBYI or IMDX more profitable?

Do analysts rate PBYI or IMDX?

Which has more volatility & risk, PBYI or IMDX?

Do insiders & institutionals hold more shares of PBYI or IMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools